ArticleResearch square2026
RNA with Azvudine Incorporated One Nucleotide Upstream of 3'-End Resists Cleavage by SARS-CoV-2 Proofreading Exonuclease.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The cytidine analog Azvudine (Azv) showed promising therapeutic effects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), leading to its conditional authorization as a COVID-19 treatment in China. Once Azvudine enters infected cells, it is converted to the active form, Azvudine-triphosphate, which has been shown to inhibit polymerases of several viruses. Here we show that when Azvudine is incorporated into RNA by the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), it hinders incorporation of the subsequent nucleotide. However, the 3'-Azv-terminated RNA does not show any resistance to the SARS-CoV-2 proofreading exonuclease (ExoN). Furthermore, we found that the incorporation of Azvudine at the penultimate position of the RNA prevents RNA cleavage by the ExoN. These findings may provide molecular insight for the development of novel nucleotide analogs that can inhibit RdRp and resist the viral proofreading mechanism of coronaviruses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.